Friday, 13 November 2026European Markets

ODFJELL TECHNOLOGY Stock Is 27% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ODFJELL TECHNOLOGY (Oslo Børs All-share Index_GI: OTL.OL) rose by a staggering 27.41% in 21 sessions from $28.53 to $36.35 at 13:47 EST on Monday, following the last session's upward trend. Oslo Børs All-share Index_GI is sliding 0.89% to $1,365.78, after consecutive sessions in a row of losses.

ODFJELL TECHNOLOGY's last close was $36.50, 13.34% below its 52-week high of $42.12.

About ODFJELL TECHNOLOGY

Odfjell Technology Ltd., a technology and engineering company, provides well, drilling, and engineering services in Norway, Europe, the Middle East, Asia, and the United Kingdom. It offers tubular and casing running, drilling tool rental, fishing, wellbore clean-up, and casing while drilling services; crew for drilling and maintenance on fixed or floating platforms; smart circulation tools; downhole tools; wired drill pipes; integrated solutions for plug and abandonment markets; and maintenance and recertification services for drilling equipment. The company also provides upgrades and modifications of drilling units; special periodic surveys; rig recertifications; yard stays; engineering and project management; marine and operability analysis; offshore execution, installation, and construction; energy mapping and reduction; and inspection and integrity management services. It serves oil and gas and oil service companies, and rig owners. The company was founded in 1973 and is based in Aberdeen, the United Kingdom. As of March 31, 2022, Odfjell Technology Ltd. operates as a stand alone company.

Volume

Today's last reported volume for ODFJELL TECHNOLOGY is 74707 which is 29.25% below its average volume of 105600.

More news about ODFJELL TECHNOLOGY (OTL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com